MYPT-1 phosphorylation was significantly higher in untreated ADPKD patients compared to that in both tolvaptan-treated ADPKD patients and healthy subjects: 0.96 ± 0.28 vs. 0.68 ± 0.09 densitometric units, p = 0.013 and vs. 0.47 ± 0.13 densitometric units, p < 0.001, respectively (Figure 2). Here, PPP1R12A is linked to autosomal dominant polycystic kidney disease.